Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Karyopharm Therapeutics (KPTI) Depreciation & Amortization (CF) (2016 - 2025)

Karyopharm Therapeutics' Depreciation & Amortization (CF) history spans 14 years, with the latest figure at $19000.0 for Q4 2025.

  • For Q4 2025, Depreciation & Amortization (CF) fell 76.54% year-over-year to $19000.0; the TTM value through Dec 2025 reached $296000.0, down 12.94%, while the annual FY2025 figure was $296000.0, 12.94% down from the prior year.
  • Depreciation & Amortization (CF) reached $19000.0 in Q4 2025 per KPTI's latest filing, down from $121000.0 in the prior quarter.
  • In the past five years, Depreciation & Amortization (CF) ranged from a high of $290000.0 in Q1 2023 to a low of $19000.0 in Q4 2025.
  • Average Depreciation & Amortization (CF) over 5 years is $128800.0, with a median of $102000.0 recorded in 2022.
  • Peak YoY movement for Depreciation & Amortization (CF): soared 63.84% in 2023, then crashed 76.54% in 2025.
  • A 5-year view of Depreciation & Amortization (CF) shows it stood at $139000.0 in 2021, then fell by 18.71% to $113000.0 in 2022, then crashed by 31.86% to $77000.0 in 2023, then increased by 5.19% to $81000.0 in 2024, then crashed by 76.54% to $19000.0 in 2025.
  • Per Business Quant, the three most recent readings for KPTI's Depreciation & Amortization (CF) are $19000.0 (Q4 2025), $121000.0 (Q3 2025), and $78000.0 (Q2 2025).